As biopharmaceutical manufacturing grows in the Gulf and the wider region, many new facilities face the same early decision: build around stainless steel, go single-use, or combine the two. Single-use bioprocessing in the Middle East is attractive for new plants that need speed and flexibility, but it is not the right answer for every process. This article sets out where single-use systems earn their place, where stainless steel still wins, and the questions to settle before committing.
What single-use actually replaces
In a traditional facility, fluids move through fixed stainless-steel vessels, pipework and valves. Between batches everything is cleaned in place, sterilised in place, and the cleaning is validated. Single-use systems replace those fixed components with pre-sterilised, disposable parts: bags for mixing and storage, tubing and sterile connectors, filter capsules, and bioreactor vessels. After the batch, the product-contact components are discarded.
The change affects much more than equipment. It removes most cleaning validation, reduces the demand for purified water and clean steam, shortens changeover between products, and moves the risk from cleaning to the supply and quality of the disposable components.
Where single-use makes sense
| Situation | Why single-use helps |
|---|---|
| Multi-product facilities | Fast changeover with no risk of carry-over between products |
| Clinical and early commercial scale | Lower capital cost while demand is uncertain |
| New facilities with tight timelines | Less fixed pipework to design, install and qualify |
| Processes with high cleaning burden | Removes cleaning validation for product-contact parts |
| Potent or sensitive products | Closed, disposable flow paths simplify containment |
| Cell and gene therapy | Small batches and closed processing suit disposable systems |
Where stainless steel can still win
Single-use has limits. At very large scale, the maximum practical size of disposable bags and bioreactors can become a constraint. For a single product running continuously at high volume, the recurring cost of disposables can outweigh the cleaning savings. Some processes involve solvents or conditions that disposable polymers do not tolerate well.
There are also operational considerations. Single-use depends on a reliable supply of qualified components; a shortage of one bag or connector can stop production. Waste volume increases, which matters where waste handling is expensive or regulated. Many manufacturers therefore adopt hybrid facilities, using single-use where flexibility and speed matter most and stainless steel where scale and continuity dominate.
Extractables and leachables
Every material that touches the product must be shown not to compromise it. For single-use components this is assessed through extractables, compounds that can be released from the polymer under aggressive laboratory conditions, and leachables, compounds that actually migrate into the product under real process conditions.
Suppliers generally provide extractables data under standardised protocols. The manufacturer then assesses risk for each component based on contact time, temperature, the solution in contact and the proximity to the final product. Components close to the final product, such as final filters and fill assemblies, attract the most scrutiny.
Integrity and sterility assurance
A single-use system replaces a validated clean piece of steel with an assembly that is sterilised by the supplier, usually by gamma irradiation or another validated method. The user must be confident that the assembly arrives sterile and stays intact through handling and use.
This is managed through supplier qualification, incoming inspection, careful handling procedures and, where appropriate, integrity testing of assemblies and filters. Sterile connectors and welders allow components to be joined without opening the system. For sterilising filters within an assembly, EU GMP Annex 1 expectations on pre-use integrity testing should be designed in from the start.
Automation in single-use processes
A common misconception is that single-use means manual. In fact automation is often what makes single-use processes reproducible at scale. Automated pumps, sensors and control software handle filtration, transfers and filling consistently and record every step for the batch record.
Parker incorporates SciLog technology into scalable, automated single-use bioprocessing systems for upstream and downstream applications, configurable as manual, semi-automated or fully automated. Upstream, Eppendorf's bioprocess portfolio offers scalable hardware and software from R&D through process development and pilot to production, so conditions developed at bench scale can be carried forward.
Questions to settle before you commit
- What scale and utilisation do you expect over the next five years? Build a cost model that includes disposables, labour, water, energy and waste.
- How many products will share the facility? More products favour single-use.
- Which unit operations benefit most? Media and buffer preparation, storage and final filtration are common starting points.
- Can your supply chain support it? Qualify more than one source where possible and agree lead times and safety stock.
- How will you handle extractables and leachables? Collect supplier data early and plan your risk assessment.
- What level of automation fits your team? Match automation to batch size, staffing and data-integrity requirements.
A phased path to adoption
Few facilities switch everything at once. A phased approach lets a team build experience and data before single-use becomes critical to supply.
Phase one usually covers low-risk, high-effort steps: media and buffer preparation in mixing bags, storage bags for intermediates, and single-use filter capsules. These deliver quick savings in cleaning and changeover without touching the most sensitive steps.
Phase two moves into core unit operations, such as single-use bioreactors for seed trains or production at clinical scale, and pre-assembled transfer and filtration manifolds.
Phase three addresses the final steps, such as final filtration and filling assemblies, where extractables, integrity and sterility assurance receive the closest attention.
At each phase, record what worked: component performance, handling issues, supply lead times and any deviations. That record becomes the evidence base for the next step and for regulators who ask how the risk was managed.
Single-use bioprocessing in the Middle East: regional considerations
For facilities in the UAE, Saudi Arabia and Egypt, lead times for imported components and the availability of local technical support are practical factors in the decision. Holding adequate stock of critical disposables and having a supplier able to respond locally reduces the risk of interruptions. Waste handling arrangements should also be confirmed early, since disposable systems increase the volume of plastic waste leaving the facility.
How Arab Lab can help
Arab Lab supplies process filtration and single-use systems from Parker and bioprocess equipment from Eppendorf across the region. If you are planning a new line or deciding between single-use and stainless steel, describe your process and scale through the contact page and our team will discuss the options with you.
